Keryx' phosphate binder set for filing following impressive Phase III
This article was originally published in Scrip
Keryx Biopharmaceuticals said it anticipates US and European regulatory submissions for Zerenex (ferric citrate; KRX-0502) in the second quarter of 2013, after reporting top-line data showing that a Phase III study investigating the treatment for hyperphosphataemia in end-stage renal disease (ESRD) patients on dialysis met the primary and all key secondary endpoints.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.